Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine

被引：10

作者：

Smith, S. P. ^{[1
]}

Baxendale, H. E. ^{[2
,3
]}

Sterling, J. C. ^{[1
,3
]}

机构：

[1] Cambridge Univ Hosp, NHS Fdn Trust, Dept Dermatol, Cambridge CB2 0QQ, England

[2] Papworth Hosp, NHS Fdn Trust, Dept Clin Immunol, Papworth Everard, England

[3] Univ Cambridge, Dept Med, Cambridge, England

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2017年 / 42卷 / 03期

关键词：

HPV VACCINATION; CUTANEOUS WARTS; RESOLUTION; RESPONSES;

D O I：

10.1111/ced.13038

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Human papillomavirus (HPV)-induced cutaneous warts are potentially serious and debilitating. In immunosuppressed patients, these warts may be resistant to standard therapies. We report a case of a young patient with a primary immune deficiency whose recalcitrant cutaneous warts regressed completely following administration of a quadrivalent HPV vaccine.

引用

页码：306 / 308

页数：3

共 50 条

[31] Risk of Guillain-Barre Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink
Gee, Julianne
Sukumaran, Lakshmi
Weintraub, Eric
VACCINE, 2017, 35 (43) : 5756 - 5758
[32] The relationship between the recurrence rate of genital warts and administration of quadrivalent human papilloma virus vaccine in women
Asl, Fatemeh Momeni
Ghaffari, Parvin
Safari, Mitra
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2025, 111 (02)
[33] Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy
Bukowinski, Anna T.
Hall, Clinton
Chang, Richard N.
Gumbs, Gia R.
Conlin, Ava Marie S.
VACCINE, 2020, 38 (37) : 5933 - 5939
[34] Recalcitrant Cutaneous Warts Treated With Recombinant Quadrivalent Human Papillomavirus Vaccine (Types 6, 11, 16, and 18) in a Developmentally Delayed, 31-Year-Old White Man
Venugopal, Supriya S.
Murrell, Dedee F.
ARCHIVES OF DERMATOLOGY, 2010, 146 (05) : 475 - 477
[35] Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts
Fouda, Ibrahim
Mohammed, Hassan Abou Khodair
Mohammed, Ghada Mohammed Yousef
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (02):
[36] Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts
Marei, Ayman
Nofal, Ahmad
Alakad, Rania
Abdel-Hady, Amina
JOURNAL OF COSMETIC DERMATOLOGY, 2020, 19 (03) : 758 - 762
[37] Recalcitrant verruca plana responding to human papillomavirus quadrivalent (types 6,11,16, and 18) vaccine, recombinant
Funke, Alisa
Fowler, Joseph
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB88 - AB88
[38] ORAL WARTS IN A PEDIATRIC PATIENT WITH TRISOMY 21 SUCCESSFULLY TREATED WITH HUMAN PAPILLOMAVIRUS VACCINE
Grohman, R.
Fox, E.
Loeber, S.
Eisenberg, R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S141 - S141
[39] Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine
Rowhani-Rahbar, Ali
Alvarez, Frances B.
Bryan, Janine T.
Hughes, James P.
Hawes, Stephen E.
Weiss, Noel S.
Koutsky, Laura A.
JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (03) : 239 - 243
[40] Patient Adherence to Three Dose Completion of the Quadrivalent Human Papillomavirus (HPV) Vaccine in a Private Practice
Rubin, Rochelle F.
Kuttab, Huda-Marie
Rihani, Rami S.
Reutzel, Thomas J.
JOURNAL OF COMMUNITY HEALTH, 2012, 37 (06) : 1145 - 1150

← 1 2 3 4 5 →